Detalhe da pesquisa
1.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood
; 143(16): 1616-1627, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215395
2.
Acute myeloid leukaemia.
Lancet
; 401(10393): 2073-2086, 2023 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068505
3.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10388): 1571-1583, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116523
4.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood
; 140(2): 112-120, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427411
5.
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
Haematologica
; 109(2): 401-410, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37534515
6.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407545
7.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood
; 137(6): 751-762, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929488
8.
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.
Haematologica
; 108(1): 42-47, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833298
9.
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 108(3): 705-716, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226495
10.
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Hematol Oncol
; 41(4): 743-752, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086447
11.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med
; 381(5): 432-443, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31365801
12.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
N Engl J Med
; 381(18): 1728-1740, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31665578
13.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
14.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med
; 379(26): 2517-2528, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501481
15.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
16.
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Blood
; 133(14): 1548-1559, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658992
17.
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
Blood
; 131(25): 2782-2788, 2018 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29618479
18.
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Blood
; 132(11): 1125-1133, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30045838
19.
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Blood
; 131(4): 387-396, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196412
20.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood
; 131(13): 1415-1424, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348128